The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

We want to know more about what these products are doing,” said Dr. Vinay Prasad during a recent FDA livestreamed ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

FDA Commissioner Marty Makary named Vinay Prasad, a hematologist oncologist and critic of the Covid-19 vaccine for children, as the next director of the Center for Biologics and Research.

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene therapies, and blood supply.

Vinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and gene therapy regulation.

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...

WASHINGTON — Vinay Prasad, an academic and fierce ... including the Center for Biologics Evaluation and Research, the unit he will now lead. After reports of his appointment, the S&P Biotech ...

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...